Dopamine News and Research RSS Feed - Dopamine News and Research

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.
New scaffold technology could someday help treat Parkinson's disease, other brain-related conditions

New scaffold technology could someday help treat Parkinson's disease, other brain-related conditions

Scientists at Rutgers and Stanford universities have created a new technology that could someday help treat Parkinson's disease and other devastating brain-related conditions that affect millions of people. [More]
New 3D micro-scaffold technology promotes reprogramming of stem cells into neurons

New 3D micro-scaffold technology promotes reprogramming of stem cells into neurons

National Institutes of Health-funded scientists have developed a 3D micro-scaffold technology that promotes reprogramming of stem cells into neurons, and supports growth of neuronal connections capable of transmitting electrical signals. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Scientists discover brain mechanisms that separate food consumption from cravings

Scientists discover brain mechanisms that separate food consumption from cravings

Researchers investigating eating disorders often study chemical and neurological functions in the brain to discover clues to overeating. Understanding non-homeostatic eating -- or eating that is driven more by palatability, habit and food cues -- and how it works in the brain may help neuroscientists determine how to control cravings, maintain healthier weights and promote healthier lifestyles. Scientists at the University of Missouri recently discovered the chemical circuits and mechanisms in the brain that separate food consumption from cravings. Knowing more about these mechanisms could help researchers develop drugs that reduce overeating. [More]
Geneticists explore evolution of musical aptitude

Geneticists explore evolution of musical aptitude

Geneticists at the University of Helsinki and the National University of Singapore have teamed up to explore the evolution of musical aptitude in the first-ever empirical study of the evolution of music. [More]
Polyunsaturated lipids can alter binding rate of two receptors involved in Parkinson's and Alzheimer's

Polyunsaturated lipids can alter binding rate of two receptors involved in Parkinson's and Alzheimer's

A study published in the prestigious journal Scientific Reports from the Nature group demonstrates, for the first time and using computational tools, that polyunsaturated lipids can alter the binding rate of two types of receivers involved in certain nervous system diseases. [More]
CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

The Centre for Addiction and Mental Health and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. [More]
Scientists develop new optical technique to observe neurotransmitter activity of individual synapses

Scientists develop new optical technique to observe neurotransmitter activity of individual synapses

Columbia University scientists have developed a new optical technique to study how information is transmitted in the brains of mice. Using this method, they found that only a small portion of synapses -- the connections between cells that control brain activity--may be active at any given time. [More]
Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

Experts at the University of Pittsburgh School of Medicine are leading the second arm of a clinical trial using gene therapy to relieve the symptoms of tremor and mobility impairment in patients with Parkinson's disease. [More]
Regrowing dopaminergic neurons may lead to new therapy for Parkinson's disease

Regrowing dopaminergic neurons may lead to new therapy for Parkinson's disease

While scientists are unsure of the molecular causes of Parkinson's Disease, they do know the disorder's tremors and other motor dysfunctions are linked to a loss of dopaminergic neurons located in the substantia nigra, a structure in the midbrain. [More]
Researchers report first-ever link between noradrenergic neurons and vulnerability to depression

Researchers report first-ever link between noradrenergic neurons and vulnerability to depression

The team of Bruno Giros, a researcher at the Douglas Mental Health University Institute and professor of psychiatry at McGill University, reports the first-ever connection between noradrenergic neurons and vulnerability to depression. Published in the journal Nature Neuroscience, this breakthrough paves the way for new depression treatments that target the adrenergic system. [More]
Human brains prioritize and reinforce high-reward memories

Human brains prioritize and reinforce high-reward memories

Why do we remember some events, places and things, but not others? Our brains prioritize rewarding memories over others, and reinforce them by replaying them when we are at rest, according to new research from the University of California, Davis, Center for Neuroscience, published Feb. 11 in the journal Neuron. [More]
Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Wayne State inks exclusive license agreement with TRImaran Pharma for novel class of drugs

Wayne State University recently entered into an exclusive license agreement with TRImaran Pharma Inc. for a class of novel drugs developed at Wayne State University that aims to offer hope in the treatment of post-traumatic stress disorders (PTSD), depression, ADHD and other neurological disorders. [More]
Study could open door for new treatment targets to help Parkinson's disease patients walk more easily

Study could open door for new treatment targets to help Parkinson's disease patients walk more easily

Two secrets of one of the brain's most enigmatic regions have finally been revealed. In a pair of new studies, scientists from the Gladstone Institutes have discovered a specific neural circuit that controls walking, and they found that input to this circuit is disrupted in Parkinson's disease. [More]
TSRI scientists discover molecular ‘switch’ that could reduce nicotine addiction

TSRI scientists discover molecular ‘switch’ that could reduce nicotine addiction

Scientists at The Scripps Research Institute have discovered that a lipid in brain cells may act as a “switch” to increase or decrease the motivation to consume nicotine. [More]
Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s. [More]
New treatment strategy may take pain away

New treatment strategy may take pain away

A brain region controlling whether we feel happy or sad, as well as addiction, is remodeled by chronic pain, reports a new Northwestern Medicine study. [More]
Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

Novel drug candidate prevents nerve cell damage in mouse model of Parkinson's disease

A team of scientists at the University of Nebraska Medical Center (UNMC) and Longevity Biotech, Inc., has demonstrated that neuroprotection could be attained in preclinical models by a novel drug candidate that changes immune responses. [More]
Antibiotic resistance may help find drugs to combat amyloid formation

Antibiotic resistance may help find drugs to combat amyloid formation

Amyloid diseases such as Parkinson's, Alzheimer's and type-2 diabetes pose a particular problem for drug designers because they do not present a clear target structure to aim at. [More]
UB researchers develop a way to ramp up conversion of skin cells into dopamine neurons

UB researchers develop a way to ramp up conversion of skin cells into dopamine neurons

For decades, the elusive holy grail in Parkinson's disease research has been finding a way to repair faulty dopamine neurons and put them back into patients, where they will start producing dopamine again. Researchers have used fetal material, which is difficult to obtain and of variable quality. Embryonic stem cells represented a tremendous innovation, but making dopamine neurons from stem cells is a long process with a low yield. [More]
Advertisement